Where is Akeso headquartered?
Akeso, Inc. is a leading biopharmaceutical company specializing in the research, development, and commercialization of innovative antibody-based therapies for oncology and immunology, with its corporate headquarters located in Zhongshan, Guangdong Province, China. From its primary executive and research campus, the company directs a robust pipeline of novel drug candidates through clinical trials and regulatory approval processes. Akeso has established itself as a key player in the global biotechnology industry by focusing on complex drug discovery and large-scale manufacturing capabilities. The company’s Zhongshan headquarters houses state-of-the-art laboratory facilities, management offices, and administrative teams that coordinate its expansion into international markets and its collaborative research efforts globally.
Related FAQs
The acronym IASO can represent several distinct organizations and historical terms depending on the professional context.
Evaluating whether Akeso (9926.HK) represents a favorable equity purchase involves analyzing its clinical pipeline of bispecific antibodies, licensing partnership revenues, and market positioning in global oncology.
The United States Food and Drug Administration periodically withdraws approval for specific pharmaceutical drugs due to emerging safety concerns, lack of demonstrated clinical efficacy, or post-market complications.
Akeso, Inc. enjoys robust long-term growth prospects driven by its innovative biopharmaceutical pipeline focused on bispecific antibodies and next-generation oncology therapeutics.
Determining the price volatility of Alignment Healthcare—a Medicare Advantage insurance provider—indicates a moderate to high volatility profile characteristic of specialized healthcare and managed care equities.
Therapeutic candidates developed by Akeso—such as its novel PD-1 blocking antibodies and bispecific immunotherapy combinations—function directly as advanced oncology immunotherapy treatments.
In English translation and classical etymology, the name Akeso derives from the ancient Greek mythological figure Akeso, who was the goddess of healing, curing processes, and the curing of illnesses.
The largest biotechnology and pharmaceutical research enterprise in China is WuXi AppTec, alongside major industry leaders like BeiGene.
Akeso, Inc. is a prominent biopharmaceutical enterprise founded, headquartered, and operating primarily in China, focusing heavily on the research, development, and commercialization of breakthrough antibody drugs for oncology and immunology.
The proper name Akeso originates from Greek mythology, where Akeso was revered as the goddess of curing, healing processes, and medical recovery, acting as a daughter of Asclepius. Etymologically, the name means healing, process of cure, or remedy.
Determining whether to use Aceso or Akeso depends entirely on the specific context, as both spellings refer to distinct entities or mythological figures.
Immunotherapy has revolutionized modern oncology and the management of various complex diseases by harnessing the patient's own immune system to target and destroy malignant cells.
Akeso, Inc. is listed on the Stock Exchange of Hong Kong under the stock code 09926, trading at approximately HK$93.20.
Akeso has achieved significant international regulatory milestones, securing official United States Food and Drug Administration approval for its flagship innovative biologic therapies, such as penpulimab-kcqx, for the treatment of advanced nasophary...
Completing two years of immunotherapy is a common clinical milestone for many cancer patients treated with immune checkpoint inhibitors, as clinical trials frequently design treatment courses to last for this specific duration.
Evaluating whether immunotherapy cancer treatments are successfully engaging the immune system involves monitoring specific clinical and physiological indicators.
The corporate mission of Akeso (such as Akeso Biopharma) centers on developing breakthrough, affordable, and high-quality therapeutic antibody drugs targeting global unmet medical needs in oncology, immunology, and major disease categories.
Akeso is a specialized nutritional or pharmaceutical product formulation, and its exact ingredient profile depends heavily on the specific variant or localized market preparation.
Akeso specializes extensively in engineering and developing advanced monoclonal antibodies, bispecific antibodies, and multi-targeting fusion proteins designed to treat complex oncological and autoimmune diseases.
Akeso tablets are specialized pharmaceutical formulations prescribed by healthcare professionals for targeted therapeutic treatments, pain management, or specific clinical conditions depending on the exact medical formulation.